Healthcare -
Biotechnology - NASDAQ - DE
$ 2.65
2.32 %
$ 594 M
Market Cap
5.2
P/E
1. INTRINSIC VALUE
Balance Sheet
CureVac N.V.
| Current Assets | 478 M |
| Cash & Short-Term Investments | 405 M |
| Receivables | 39.5 M |
| Other Current Assets | 33.8 M |
| Non-Current Assets | 310 M |
| Long-Term Investments | -4 K |
| PP&E | 279 M |
| Other Non-Current Assets | 31.2 M |
| Current Liabilities | 186 M |
| Accounts Payable | 46.4 M |
| Short-Term Debt | 5 M |
| Other Current Liabilities | 135 M |
| Non-Current Liabilities | 84.9 M |
| Long-Term Debt | 36.8 M |
| Other Non-Current Liabilities | 48.1 M |
EFFICIENCY
Earnings Waterfall
CureVac N.V.
| Revenue | 53.8 M |
| Cost Of Revenue | 124 M |
| Gross Profit | -70.6 M |
| Operating Expenses | 204 M |
| Operating Income | -274 M |
| Other Expenses | -14 M |
| Net Income | -260 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CureVac N.V.
| Net Income | -260 M |
| Depreciation & Amortization | 23.4 M |
| Capital Expenditures | -55.2 M |
| Stock-Based Compensation | 7.7 M |
| Change in Working Capital | -68.3 M |
| Others | 45.4 M |
| Free Cash Flow | -323 M |
Wall Street Analysts Price Targets
CureVac N.V.
CVAC has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CVAC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CureVac N.V.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes novel tumor epitopes identified through proprietary whole genome-based discovery platform Enhanced Combination Therapy: CVHNLC to be tested in combination with pembrolizumab, aiming to amplify targeted anti-tumor immune responses Clinical Progress: Patient treatment anticipated to start in the second half of 2025 Pipeline Advancement: IND clearance highlights CureVac's continued oncology pipeline growth, with more candidates planned to enter the clinic in 2026 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / April 7, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small cell lung cancer (sqNSCLC).
accessnewswire.com
- 2 weeks ago
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
benzinga.com
- 3 weeks ago
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
reuters.com
- 3 weeks ago
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / March 27, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
accessnewswire.com
- 3 weeks ago
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®.
accessnewswire.com
- 2 months ago
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025.
seekingalpha.com
- 3 months ago
2 Small-Cap Stocks Set to Shine in a Bull Market
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
marketbeat.com
- 4 months ago
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
zacks.com
- 4 months ago
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants Charlie Yang - Bank of America Merrill Lynch CJ Yeh - Leerink Partners Roy Buchanan - Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call.
seekingalpha.com
- 5 months ago
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.
accesswire.com
- 5 months ago
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024.
accesswire.com
- 5 months ago
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.
accesswire.com
- 5 months ago
8. Profile
Summary
CureVac N.V. CVAC
COUNTRY
DE
INDUSTRY
Biotechnology
MARKET CAP
$ 594 M
Dividend Yield
0.00%
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Contact
Friedrich-Miescher-Strasse 15, Tübingen, 72076
https://www.curevac.com
IPO
Date
Aug. 14, 2020
Employees
999
Officers
Mr. Marco Rau L.L.M., Ph.D.
General Counsel
Mr. Axel-Sven Malkomes
Chief Financial Officer & Member of Executive Board
Dr. Malte Greune Ph.D.
Chief Operating Officer, Member of Management Board & MD
Dr. Myriam Mendila M.D.
Chief Scientific Officer, Head of R&D, MD & Member of the Management Board
Dr. Ulrike Gnad-Vogt M.D., Ph.D.
Senior Vice President & Area Head of Oncology
Mr. Thaminda Ramanayake
Chief Business Officer & Member of Executive Board
Dr. Alexander Zehnder M.B.A., M.D.
Chief Executive Officer, MD & Member of Management Board
Dr. Sarah Fakih
Vice President Corporate Communications & Investor Relations
Slavica Stevanovic-Heck
Head of Human Resources
Dr. Patrick Baumhof
Senior Vice President of Technology